Methotrexate (MTX) remains the predominant medication used by rheumatologists to treat rheumatoid arthritis (RA). Doses of 7.5–25 mg per week with daily folic acid are generally prescribed. Despite its common use, MTX must be prescribed cautiously given the potential adverse effects when taken incorrectly or without folic acid supplementation. Cases of MTX-induced cutaneous ulceration have…
Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…
Asthma, Allergic Disease, Passive Smoke Exposure & the Risk of RA
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases. One hypothesis is that inflammation in the respiratory tract results in autoantibody formation that later leads to disease. Kronzer et al. set out to narrow the knowledge gaps related to the oral-respiratory factors that may mediate RA pathogenesis.
A More Complicated Pregnancy: Inflammatory Arthritis Increases the Risk for Adverse Outcomes
Pregnant women with inflammatory arthritis may have an increased risk for preterm delivery. New research examined the risk of preterm delivery and other pregnancy complications in women with RA and JIA vs. healthy controls…
RheumPAC Advocates for Department of Defense Arthritis Research Funding
The ACR’s nonpartisan political action committee is continuing to advocate for increased defense department funding for rheumatology research. Learn about RheumPAC’s efforts and how you can help.
The Prevalence, Incidence, Mortality & Costs of RA-Related ILD
Interstitial lung disease (ILD) can be associated with rheumatoid arthritis (RA) with significant morbidity and mortality. An article in The Journal of Rheumatology focused on calculating the prevalence, incidence, mortality and costs to the healthcare system of RA-related ILD (RA-ILD).1 “RA is the most common of connective tissue diseases encountered by rheumatologists—affecting about 1% of…
The Rescue: Moving RA Patients from Adalimumab to Baricitinib
The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…
Eosinophilic Gastroenteritis & Eosinophilic Ascites Associated with RA
Eosinophilic gastroenteritis (EGE) is a rare condition caused by eosinophilic infiltration of the gastrointestinal (GI) tract. The condition is subdivided into the GI layers it affects: mucosal, muscular and subserosal.1 EGE usually presents with non-specific GI symptoms, such as impaired motility, intestinal obstruction and, rarely, ascites.2 Below, we report a rare case of EGE leading…
Biological DMARDs in Elderly RA Patients: Use, Maintenance & Discontinuation
A study comparing seven biologic DMARDs in RA patients aged 65 years and older found abatacept had the highest retention rate and the lowest discontinuation rate…
New Research Examines the Use of Natural Dietary Supplements by RA Patients
The popularity of natural dietary supplements has grown worldwide, with many adults using them to manage musculoskeletal conditions. But for RA patients, little is known about the risk of side effects and potential adverse drug interactions when taking these supplements with standard RA therapies. New research examined the supplement use patterns of RA patients…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 74
- Next Page »